达兰西普治疗持续性或复发性上皮性卵巢癌的II期评估:NRG肿瘤学/妇科肿瘤学组研究
本研究为II期试验,评估达兰西普(可溶性ALK1抑制剂受体融合蛋白)在持续性或复发性卵巢癌及相关恶性肿瘤患者中的疗效。达兰西普1.2 mg/kg每3周皮下给药,30例可评估患者中无客观缓解,6个月无事件生存率为20%(6/30,90%CI 9.1%–35.7%),治疗相关3级不良事件6例,无≥4级不良事件,结论为总体疗效有限但安全性可接受。
要点
- 30例可评估患者中无客观缓解,6个月无事件生存率为20%(6/30,90%CI 9.1%–35.7%)。
- 治疗相关3级不良事件6例,无≥4级不良事件。
- 所有患者均停用达兰西普,80.0%因疾病进展、16.7%因毒性、3.3%因其他原因。
核心结论
- 达兰西普在该患者群体中虽安全但总体疗效有限。
研究设计与样本
- II期单臂研究,纳入持续性或复发性卵巢癌及相关恶性肿瘤患者,要求可测量病灶、既往1–2线细胞毒方案、GOG体力状态评分≤2。
- 达兰西普1.2 mg/kg每3周皮下注射直至疾病进展或出现不可接受毒性;第一阶段入组30例后关闭。
- 主要零假设为缓解概率≤0.10且6个月无进展生存(未接受非方案治疗,EFS6)概率≤0.15,采用RECIST 1.1标准。
主要发现
- 30例入组患者中位年龄56.5岁,高级别浆液性组织学占76.7%,既往2线方案占46.7%,无铂间期<6个月占73.3%。
- 所有患者均停用达兰西普,24例(80.0%)因疾病进展、5例(16.7%)因毒性、1例(3.3%)因其他原因。
- 每例患者中位治疗周期数为2(范围1–29)。
- 治疗相关3级不良事件6例,无≥4级不良事件;无客观缓解。
- EFS6为20%(6/30,90%CI 9.1%–35.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor fusion protein, in patients with persistent or recurrent ovarian carcinoma and related malignancies. METHODS: Eligibility criteria included measurable disease, 1-2 prior cytotoxic regimens and GOG performance status (PS) ≤2. Dalantercept was administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or development of unacceptable toxicity. The primary null hypothesis was the probability of response ≤0.10 and the probability of 6-month progression-free survival without receipt of non-protocol therapy (event-free survival at 6 months, EFS6) ≤0.15, using RECIST 1.1 criteria. RESULTS: The first stage was closed after enrollment of 30 participants with median age of 56.5 years, high-grade serous histology in 76.7%, 2 prior regimens in 46.7%, and platinum-free interval <6 months in 73.3%. All participants discontinued dalantercept, 24 (80.0%), 5 (16.7%) and 1 (3.3%) due to progression, toxicity, and other reason, respectively. The median number of treatment cycles per patient was 2 (range 1-29). There were six treatment-related grade 3 AEs and no grade ≥4 AEs. There were no objective responses. EFS6 was reached in 20% (6 out of 30 participants, 90% CI 9.1% to 35.7%). CONCLUSIONS: Though safe, dalantercept as administered had limited efficacy in this patient population overall.
引用
- Burger RA, Deng W, Makker V, et al. Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018. PMID: 30041929. doi:10.1016/j.ygyno.2018.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。